The additional type II FLT3 inhibitor Quizartinib, type 2 FLT3 inhibitor was tested in recent clinical trial (QuANTUM-First) in combination with induction therapy in newly diagnosed FLT3-ITD+ AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.